If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> VOLUME 113 NUMBER 1 JANUARY 2018<br /> www.nature.com/ajg<br /> OFFICIAL PUBLICATION OF THE AMERICAN COLLEGE OF GASTROENTEROLOGY<br /> EDITORS: Brian E. Lacy, PhD, MD, FACG and Brennan Spiegel, MD, MSHS, FACG<br /> VOLUME 113 NUMBER 6 JUNE 2018<br /> www.nature.com/ajg<br /> OFFICIAL PUBLICATION OF THE AMERICAN COLLEGE OF GASTROENTEROLOGY<br /> LEADING ARTICLES OF THE MONTH<br /> Review Article<br /> 819 The Gastroenterologist's Guide to Management of the Post-Liver<br /> Transplant Patient CME<br /> David M. Chascsa and Hugo E. Vargas<br /> Esophagus<br /> 836 The Natural Course of Eosinophilic Esophagitis and Long-Term<br /> Consequences of Undiagnosed Disease In A Large Cohort<br /> Marijn J. Warners, Renske A. B. Oude Nijhuis,<br /> Laetitia R. H. de Wijkerslooth, et al.<br /> Stomach<br /> 845 Cumulative Dose Threshold for the Chemopreventive Effect of Aspirin<<a title="AJG_Vol.113.No6 page 1" href="http://viewer.zmags.com/publication/d04ca52f?page=1"> VOLUME 113 NUMBER 1 JANUARY 2018 www.nature.com/a</a> <a title="AJG_Vol.113.No6 page 2" href="http://viewer.zmags.com/publication/d04ca52f?page=2"> VOLUME 113 NUMBER 6 JUNE 2018 www.nature.com/aj</a> <a title="AJG_Vol.113.No6 page 3" href="http://viewer.zmags.com/publication/d04ca52f?page=3"> #1PRESCRIBED MEDICATION APPROVED FOR IBS-D1* </a> <a title="AJG_Vol.113.No6 page 4" href="http://viewer.zmags.com/publication/d04ca52f?page=4"> BRIEF SUMMARY OF PRESCRIBING INFORMATION This Br</a> <a title="AJG_Vol.113.No6 page 5" href="http://viewer.zmags.com/publication/d04ca52f?page=5"> www.nature.com/ajg The American Journ</a> <a title="AJG_Vol.113.No6 page 6" href="http://viewer.zmags.com/publication/d04ca52f?page=6"> RECOMMEND THE BEST WITH NEXIUM® 24HR Nexium® 24H</a> <a title="AJG_Vol.113.No6 page 7" href="http://viewer.zmags.com/publication/d04ca52f?page=7"> da ACG POSTGRADUATE COURSE 2018 Hepatology School</a> <a title="AJG_Vol.113.No6 page 8" href="http://viewer.zmags.com/publication/d04ca52f?page=8"> Brief Summary of Prescribing Information for STEL</a> <a title="AJG_Vol.113.No6 page 9" href="http://viewer.zmags.com/publication/d04ca52f?page=9"> STELARA® (ustekinumab) Table 2: Common adverse re</a> <a title="AJG_Vol.113.No6 page 10" href="http://viewer.zmags.com/publication/d04ca52f?page=10"> The flagship journal of the American College of Ga</a> <a title="AJG_Vol.113.No6 page 11" href="http://viewer.zmags.com/publication/d04ca52f?page=11"> FOR TREATING CHRONIC HCV EXPAND WHAT'S POSSIBLE </a> <a title="AJG_Vol.113.No6 page 12" href="http://viewer.zmags.com/publication/d04ca52f?page=12"> WHAT DOES SIMPLE DOSING LOOK LIKE? TABLET ON</a> <a title="AJG_Vol.113.No6 page 13" href="http://viewer.zmags.com/publication/d04ca52f?page=13"> EPCLUSA® (sofosbuvir 400 mg and velpatasvir 100 m</a> <a title="AJG_Vol.113.No6 page 14" href="http://viewer.zmags.com/publication/d04ca52f?page=14"> Brief Summary (cont.) In ASTRAL-1, isolated, asy</a> <a title="AJG_Vol.113.No6 page 15" href="http://viewer.zmags.com/publication/d04ca52f?page=15"> INDICATIONS </a> <a title="AJG_Vol.113.No6 page 16" href="http://viewer.zmags.com/publication/d04ca52f?page=16"> In UC & CD FOR ADULTS WITH MODERATELY TO SEVERE</a> <a title="AJG_Vol.113.No6 page 17" href="http://viewer.zmags.com/publication/d04ca52f?page=17"> BRIEF SUMMARY OF FULL PRESCRIBING INFORMATION ENT</a> <a title="AJG_Vol.113.No6 page 18" href="http://viewer.zmags.com/publication/d04ca52f?page=18"> Table 2. Adverse Reactions in ≥3% of ENTYVIO-trea</a> <a title="AJG_Vol.113.No6 page 19" href="http://viewer.zmags.com/publication/d04ca52f?page=19"> with persistently positive anti-vedolizumab antib</a> <a title="AJG_Vol.113.No6 page 20" href="http://viewer.zmags.com/publication/d04ca52f?page=20"> Help patients be more proactive about their diges</a> <a title="AJG_Vol.113.No6 page 21" href="http://viewer.zmags.com/publication/d04ca52f?page=21"> 6 MILLION CASES AND GROWING GIQuIC Heightens Grow</a> <a title="AJG_Vol.113.No6 page 22" href="http://viewer.zmags.com/publication/d04ca52f?page=22"> 25 Mucosal Healing Index Score 0 </a> <a title="AJG_Vol.113.No6 page 23" href="http://viewer.zmags.com/publication/d04ca52f?page=23"> OFFICIAL PUBLICATION OF THE AMERICAN </a> <a title="AJG_Vol.113.No6 page 24" href="http://viewer.zmags.com/publication/d04ca52f?page=24"> Clinically Validated, Physician-Endorsed, Nonpres</a> <a title="AJG_Vol.113.No6 page 25" href="http://viewer.zmags.com/publication/d04ca52f?page=25"> For first-line constipation therapy, stick with t</a> <a title="AJG_Vol.113.No6 page 26" href="http://viewer.zmags.com/publication/d04ca52f?page=26"> A 39-year-old Asian female recently diagnosed wit</a> <a title="AJG_Vol.113.No6 page 27" href="http://viewer.zmags.com/publication/d04ca52f?page=27"> CONTENTS </a> <a title="AJG_Vol.113.No6 page 28" href="http://viewer.zmags.com/publication/d04ca52f?page=28"> www.nature.com/ajg </a> <a title="AJG_Vol.113.No6 page 29" href="http://viewer.zmags.com/publication/d04ca52f?page=29"> PROVIDING ACHALASIA PATIENTS WITH OPTIONS INSTEAD</a> <a title="AJG_Vol.113.No6 page 30" href="http://viewer.zmags.com/publication/d04ca52f?page=30"> NOW APPROVED! Coming soon to pharmacies Sign up a</a> <a title="AJG_Vol.113.No6 page 31" href="http://viewer.zmags.com/publication/d04ca52f?page=31">   ÌÊœőŒř ANNUAL SCIENTIFIC MEETING & P</a> <a title="AJG_Vol.113.No6 page 32" href="http://viewer.zmags.com/publication/d04ca52f?page=32"> COMING SOON from Shionogi Inc. </a> <a title="AJG_Vol.113.No6 page 33" href="http://viewer.zmags.com/publication/d04ca52f?page=33"> The week's best science, from the world's #1 scie</a> <a title="AJG_Vol.113.No6 page 34" href="http://viewer.zmags.com/publication/d04ca52f?page=34"> IMPORTANT SAFETY INFORMATION SUPREP® Bowel Prep K</a> <a title="AJG_Vol.113.No6 page 35" href="http://viewer.zmags.com/publication/d04ca52f?page=35"> #1 MOST PRESCRIBED, BRANDED BOWEL PREP KIT1 </a> <a title="AJG_Vol.113.No6 page 36" href="http://viewer.zmags.com/publication/d04ca52f?page=36"> THE RED SECTION 789 see related ed</a> <a title="AJG_Vol.113.No6 page 37" href="http://viewer.zmags.com/publication/d04ca52f?page=37"> 790 THE RED SECTION A CLARION CALL TO </a> <a title="AJG_Vol.113.No6 page 38" href="http://viewer.zmags.com/publication/d04ca52f?page=38"> THE RED SECTION 791 see related ed</a> <a title="AJG_Vol.113.No6 page 39" href="http://viewer.zmags.com/publication/d04ca52f?page=39"> 792 THE RED SECTION </a> <a title="AJG_Vol.113.No6 page 40" href="http://viewer.zmags.com/publication/d04ca52f?page=40"> THE RED SECTION 793 Table 1 Potentially</a> <a title="AJG_Vol.113.No6 page 41" href="http://viewer.zmags.com/publication/d04ca52f?page=41"> HCC with cirrhosis CPT class A or B </a> <a title="AJG_Vol.113.No6 page 42" href="http://viewer.zmags.com/publication/d04ca52f?page=42"> THE RED SECTION 795 see related ed</a> <a title="AJG_Vol.113.No6 page 43" href="http://viewer.zmags.com/publication/d04ca52f?page=43"> 796 THE RED SECTION IT APPROACH I Fig. 1 E</a> <a title="AJG_Vol.113.No6 page 44" href="http://viewer.zmags.com/publication/d04ca52f?page=44"> Fig. 4 Incision and drainage kit for acutely thro</a> <a title="AJG_Vol.113.No6 page 45" href="http://viewer.zmags.com/publication/d04ca52f?page=45"> 798 THE RED SECTION IT APPROACH I Fig. 7 F</a> <a title="AJG_Vol.113.No6 page 46" href="http://viewer.zmags.com/publication/d04ca52f?page=46"> THE RED SECTION 799 Images page x se</a> <a title="AJG_Vol.113.No6 page 47" href="http://viewer.zmags.com/publication/d04ca52f?page=47"> 800 THE RED SECTION Video see relate</a> <a title="AJG_Vol.113.No6 page 48" href="http://viewer.zmags.com/publication/d04ca52f?page=48"> CME QUESTIONS 801 CME see related edi</a> <a title="AJG_Vol.113.No6 page 49" href="http://viewer.zmags.com/publication/d04ca52f?page=49"> 802 CME QUESTIONS CME see related e</a> <a title="AJG_Vol.113.No6 page 50" href="http://viewer.zmags.com/publication/d04ca52f?page=50"> EDITORIAL 803 This Editorial links</a> <a title="AJG_Vol.113.No6 page 51" href="http://viewer.zmags.com/publication/d04ca52f?page=51"> 804 S.D. Saini, K.D. Platt COLON and 1 co</a> <a title="AJG_Vol.113.No6 page 52" href="http://viewer.zmags.com/publication/d04ca52f?page=52"> REVIEW ARTICLE 805 see related CME </a> <a title="AJG_Vol.113.No6 page 53" href="http://viewer.zmags.com/publication/d04ca52f?page=53"> 806 Mohapatra et al. REVIEW ARTICLE DESCR</a> <a title="AJG_Vol.113.No6 page 54" href="http://viewer.zmags.com/publication/d04ca52f?page=54"> Beyond O&P Times Three 807 Table 1 Epi</a> <a title="AJG_Vol.113.No6 page 55" href="http://viewer.zmags.com/publication/d04ca52f?page=55"> 808 Mohapatra et al. Invasion of the mu</a> <a title="AJG_Vol.113.No6 page 56" href="http://viewer.zmags.com/publication/d04ca52f?page=56"> in patients with a CD4 count of < 50 cell/µl. The</a> <a title="AJG_Vol.113.No6 page 57" href="http://viewer.zmags.com/publication/d04ca52f?page=57"> 810 Mohapatra et al. REVIEW ARTICLE Giard</a> <a title="AJG_Vol.113.No6 page 58" href="http://viewer.zmags.com/publication/d04ca52f?page=58"> Beyond O&P Times Three 811 Table 2 Epid</a> <a title="AJG_Vol.113.No6 page 59" href="http://viewer.zmags.com/publication/d04ca52f?page=59"> 812 Mohapatra et al. REVIEW ARTICLE are o</a> <a title="AJG_Vol.113.No6 page 60" href="http://viewer.zmags.com/publication/d04ca52f?page=60"> Fig. 3 Demonstration of pinworms (Enterobius ver</a> <a title="AJG_Vol.113.No6 page 61" href="http://viewer.zmags.com/publication/d04ca52f?page=61"> 814 Mohapatra et al. REVIEW ARTICLE Stron</a> <a title="AJG_Vol.113.No6 page 62" href="http://viewer.zmags.com/publication/d04ca52f?page=62"> Beyond O&P Times Three 815 Table 3 The </a> <a title="AJG_Vol.113.No6 page 63" href="http://viewer.zmags.com/publication/d04ca52f?page=63"> 816 Mohapatra et al. REVIEW ARTICLE SUMMA</a> <a title="AJG_Vol.113.No6 page 64" href="http://viewer.zmags.com/publication/d04ca52f?page=64"> reviewed the paper for scientific accuracy. CSP f</a> <a title="AJG_Vol.113.No6 page 65" href="http://viewer.zmags.com/publication/d04ca52f?page=65"> 818 Mohapatra et al. REVIEW ARTICLE 54. </a> <a title="AJG_Vol.113.No6 page 66" href="http://viewer.zmags.com/publication/d04ca52f?page=66"> REVIEW ARTICLE 819 see related CME </a> <a title="AJG_Vol.113.No6 page 67" href="http://viewer.zmags.com/publication/d04ca52f?page=67"> 820 D.M. Chascsa, H.E. Vargas REVIEW ARTIC</a> <a title="AJG_Vol.113.No6 page 68" href="http://viewer.zmags.com/publication/d04ca52f?page=68"> The gastroenterologist's guide to management of t</a> <a title="AJG_Vol.113.No6 page 69" href="http://viewer.zmags.com/publication/d04ca52f?page=69"> 822 D.M. Chascsa, H.E. Vargas REVIEW ARTIC</a> <a title="AJG_Vol.113.No6 page 70" href="http://viewer.zmags.com/publication/d04ca52f?page=70"> The gastroenterologist's guide to management of t</a> <a title="AJG_Vol.113.No6 page 71" href="http://viewer.zmags.com/publication/d04ca52f?page=71"> 824 D.M. Chascsa, H.E. Vargas REVIEW ARTIC</a> <a title="AJG_Vol.113.No6 page 72" href="http://viewer.zmags.com/publication/d04ca52f?page=72"> The gastroenterologist's guide to management of t</a> <a title="AJG_Vol.113.No6 page 73" href="http://viewer.zmags.com/publication/d04ca52f?page=73"> 826 D.M. Chascsa, H.E. Vargas REVIEW ARTIC</a> <a title="AJG_Vol.113.No6 page 74" href="http://viewer.zmags.com/publication/d04ca52f?page=74"> The gastroenterologist's guide to management of t</a> <a title="AJG_Vol.113.No6 page 75" href="http://viewer.zmags.com/publication/d04ca52f?page=75"> 828 D.M. Chascsa, H.E. Vargas REVIEW ARTIC</a> <a title="AJG_Vol.113.No6 page 76" href="http://viewer.zmags.com/publication/d04ca52f?page=76"> ARTICLE 829 see related editorial o</a> <a title="AJG_Vol.113.No6 page 77" href="http://viewer.zmags.com/publication/d04ca52f?page=77"> 830 Xie et al. ESOPHAGUS developed for OA</a> <a title="AJG_Vol.113.No6 page 78" href="http://viewer.zmags.com/publication/d04ca52f?page=78"> Assessing the feasibility of targeted screening f</a> <a title="AJG_Vol.113.No6 page 79" href="http://viewer.zmags.com/publication/d04ca52f?page=79"> 832 Xie et al. ESOPHAGUS Table 2 Associa</a> <a title="AJG_Vol.113.No6 page 80" href="http://viewer.zmags.com/publication/d04ca52f?page=80"> Assessing the feasibility of targeted screening f</a> <a title="AJG_Vol.113.No6 page 81" href="http://viewer.zmags.com/publication/d04ca52f?page=81"> 834 Xie et al. Line of equality </a> <a title="AJG_Vol.113.No6 page 82" href="http://viewer.zmags.com/publication/d04ca52f?page=82"> Assessing the feasibility of targeted screening f</a> <a title="AJG_Vol.113.No6 page 83" href="http://viewer.zmags.com/publication/d04ca52f?page=83"> 836 ARTICLE </a> <a title="AJG_Vol.113.No6 page 84" href="http://viewer.zmags.com/publication/d04ca52f?page=84"> impaction are typical for adults [6]. The endosco</a> <a title="AJG_Vol.113.No6 page 85" href="http://viewer.zmags.com/publication/d04ca52f?page=85"> 838 Warners et al. ESOPHAGUS including wh</a> <a title="AJG_Vol.113.No6 page 86" href="http://viewer.zmags.com/publication/d04ca52f?page=86"> 2161 EoE patients identified through pathology re</a> <a title="AJG_Vol.113.No6 page 87" href="http://viewer.zmags.com/publication/d04ca52f?page=87"> 840 Warners et al. ESOPHAGUS Table 1 Dem</a> <a title="AJG_Vol.113.No6 page 88" href="http://viewer.zmags.com/publication/d04ca52f?page=88"> 841 Table 2 Histological and serologic</a> <a title="AJG_Vol.113.No6 page 89" href="http://viewer.zmags.com/publication/d04ca52f?page=89"> 842 Warners et al. a 100p < 0.001 Ad</a> <a title="AJG_Vol.113.No6 page 90" href="http://viewer.zmags.com/publication/d04ca52f?page=90"> 100 80 Strictures, % 60 40 20 0 p = 0</a> <a title="AJG_Vol.113.No6 page 91" href="http://viewer.zmags.com/publication/d04ca52f?page=91"> 844 Warners et al. 8. 9. 10. 11</a> <a title="AJG_Vol.113.No6 page 92" href="http://viewer.zmags.com/publication/d04ca52f?page=92"> ARTICLE 845 see related editorial o</a> <a title="AJG_Vol.113.No6 page 93" href="http://viewer.zmags.com/publication/d04ca52f?page=93"> 846 Kim et al. STOMACH Notably, there</a> <a title="AJG_Vol.113.No6 page 94" href="http://viewer.zmags.com/publication/d04ca52f?page=94"> The primary outcome of this study was a newly</a> <a title="AJG_Vol.113.No6 page 95" href="http://viewer.zmags.com/publication/d04ca52f?page=95"> 848 Kim et al. STOMACH aspirin and NSAIDs</a> <a title="AJG_Vol.113.No6 page 96" href="http://viewer.zmags.com/publication/d04ca52f?page=96"> Cumulative Dose Threshold for the Chemopreventive</a> <a title="AJG_Vol.113.No6 page 97" href="http://viewer.zmags.com/publication/d04ca52f?page=97"> 850 Kim et al. STOMACH Table 2 Trend est</a> <a title="AJG_Vol.113.No6 page 98" href="http://viewer.zmags.com/publication/d04ca52f?page=98"> Cumulative Dose Threshold for the Chemopreventive</a> <a title="AJG_Vol.113.No6 page 99" href="http://viewer.zmags.com/publication/d04ca52f?page=99"> 852 Kim et al. 0.020 STOMACH Cumulat</a> <a title="AJG_Vol.113.No6 page 100" href="http://viewer.zmags.com/publication/d04ca52f?page=100"> exposure and H. pylori eradication was not statis</a> <a title="AJG_Vol.113.No6 page 101" href="http://viewer.zmags.com/publication/d04ca52f?page=101"> 854 Kim et al. STOMACH 9. Algra AM, R</a> <a title="AJG_Vol.113.No6 page 102" href="http://viewer.zmags.com/publication/d04ca52f?page=102"> ARTICLE 855 see related editorial o</a> <a title="AJG_Vol.113.No6 page 103" href="http://viewer.zmags.com/publication/d04ca52f?page=103"> 856 Ponds et al. ENDOSCOPY and its cost-e</a> <a title="AJG_Vol.113.No6 page 104" href="http://viewer.zmags.com/publication/d04ca52f?page=104"> Screening for dysplasia with Lugol chromoendoscop</a> <a title="AJG_Vol.113.No6 page 105" href="http://viewer.zmags.com/publication/d04ca52f?page=105"> 858 Ponds et al. ENDOSCOPY Table 1 Patie</a> <a title="AJG_Vol.113.No6 page 106" href="http://viewer.zmags.com/publication/d04ca52f?page=106"> Screening for dysplasia with Lugol chromoendoscop</a> <a title="AJG_Vol.113.No6 page 107" href="http://viewer.zmags.com/publication/d04ca52f?page=107"> 860 Ponds et al. ENDOSCOPY The diagno</a> <a title="AJG_Vol.113.No6 page 108" href="http://viewer.zmags.com/publication/d04ca52f?page=108"> Screening for dysplasia with Lugol chromoendoscop</a> <a title="AJG_Vol.113.No6 page 109" href="http://viewer.zmags.com/publication/d04ca52f?page=109"> 862 Ponds et al. 12. 13. 14. 15. </a> <a title="AJG_Vol.113.No6 page 110" href="http://viewer.zmags.com/publication/d04ca52f?page=110"> ARTICLE 863 see related editorial o</a> <a title="AJG_Vol.113.No6 page 111" href="http://viewer.zmags.com/publication/d04ca52f?page=111"> 864 Zamor et al. LIVER approved in the Un</a> <a title="AJG_Vol.113.No6 page 112" href="http://viewer.zmags.com/publication/d04ca52f?page=112"> than EBR 50 mg/GZR 100 mg for 12 weeks or EBR 50 </a> <a title="AJG_Vol.113.No6 page 113" href="http://viewer.zmags.com/publication/d04ca52f?page=113"> 866 Zamor et al. LIVER Table 2 Participa</a> <a title="AJG_Vol.113.No6 page 114" href="http://viewer.zmags.com/publication/d04ca52f?page=114"> Elbasvir/grazoprevir in black adults with hepatit</a> <a title="AJG_Vol.113.No6 page 115" href="http://viewer.zmags.com/publication/d04ca52f?page=115"> 868 Zamor et al. LIVER Subgroup </a> <a title="AJG_Vol.113.No6 page 116" href="http://viewer.zmags.com/publication/d04ca52f?page=116"> Elbasvir/grazoprevir in black adults with hepatit</a> <a title="AJG_Vol.113.No6 page 117" href="http://viewer.zmags.com/publication/d04ca52f?page=117"> 870 Zamor et al. LIVER Table 4 Safety an</a> <a title="AJG_Vol.113.No6 page 118" href="http://viewer.zmags.com/publication/d04ca52f?page=118"> and Sundise; and served as a consultant for Roche</a> <a title="AJG_Vol.113.No6 page 119" href="http://viewer.zmags.com/publication/d04ca52f?page=119"> 872 ARTICLE </a> <a title="AJG_Vol.113.No6 page 120" href="http://viewer.zmags.com/publication/d04ca52f?page=120"> were either naïve to or experienced with anti-TNF</a> <a title="AJG_Vol.113.No6 page 121" href="http://viewer.zmags.com/publication/d04ca52f?page=121"> 874 D'Haens et al. INFLAMMATORY BOWEL DISE</a> <a title="AJG_Vol.113.No6 page 122" href="http://viewer.zmags.com/publication/d04ca52f?page=122"> Lymphoma Risk and Overall Safety Profile of Adali</a> <a title="AJG_Vol.113.No6 page 123" href="http://viewer.zmags.com/publication/d04ca52f?page=123"> 876 D'Haens et al. OWEL DISEASE INFLAMMATO</a> <a title="AJG_Vol.113.No6 page 124" href="http://viewer.zmags.com/publication/d04ca52f?page=124"> Lymphoma Risk and Overall Safety Profile of Adali</a> <a title="AJG_Vol.113.No6 page 125" href="http://viewer.zmags.com/publication/d04ca52f?page=125"> 878 D'Haens et al. OWEL DISEASE INFLAMMATO</a> <a title="AJG_Vol.113.No6 page 126" href="http://viewer.zmags.com/publication/d04ca52f?page=126"> Injection site reaction Twelve patients (0.2%) re</a> <a title="AJG_Vol.113.No6 page 127" href="http://viewer.zmags.com/publication/d04ca52f?page=127"> 880 D'Haens et al. INFLAMMATORY BOWEL DISE</a> <a title="AJG_Vol.113.No6 page 128" href="http://viewer.zmags.com/publication/d04ca52f?page=128"> rics, Millenium/Takeda, Mitsubishi Pharma, Merck </a> <a title="AJG_Vol.113.No6 page 129" href="http://viewer.zmags.com/publication/d04ca52f?page=129"> 882 D'Haens et al. INFLAMMATORY BOWEL DISE</a> <a title="AJG_Vol.113.No6 page 130" href="http://viewer.zmags.com/publication/d04ca52f?page=130"> ARTICLE 883 see related editorial o</a> <a title="AJG_Vol.113.No6 page 131" href="http://viewer.zmags.com/publication/d04ca52f?page=131"> 884 Singh et al. INFLAMMATORY BOWEL DISEAS</a> <a title="AJG_Vol.113.No6 page 132" href="http://viewer.zmags.com/publication/d04ca52f?page=132"> Obesity and response to infliximab in patients...</a> <a title="AJG_Vol.113.No6 page 133" href="http://viewer.zmags.com/publication/d04ca52f?page=133"> 886 Singh et al. INFLAMMATORY BOWEL DISEAS</a> <a title="AJG_Vol.113.No6 page 134" href="http://viewer.zmags.com/publication/d04ca52f?page=134"> Obesity and response to infliximab in patients...</a> <a title="AJG_Vol.113.No6 page 135" href="http://viewer.zmags.com/publication/d04ca52f?page=135"> 888 Singh et al. INFLAMMATORY BOWEL DISEAS</a> <a title="AJG_Vol.113.No6 page 136" href="http://viewer.zmags.com/publication/d04ca52f?page=136"> manuscript for important intellectual content: JP</a> <a title="AJG_Vol.113.No6 page 137" href="http://viewer.zmags.com/publication/d04ca52f?page=137"> 890 ARTICLE see related editorial o</a> <a title="AJG_Vol.113.No6 page 138" href="http://viewer.zmags.com/publication/d04ca52f?page=138"> was identified [6]. However, a general cutoff con</a> <a title="AJG_Vol.113.No6 page 139" href="http://viewer.zmags.com/publication/d04ca52f?page=139"> 892 Ungar et al. DISEASE BOWEL INFLAMMATOR</a> <a title="AJG_Vol.113.No6 page 140" href="http://viewer.zmags.com/publication/d04ca52f?page=140"> were never exposed to adalimumab before. Most of </a> <a title="AJG_Vol.113.No6 page 141" href="http://viewer.zmags.com/publication/d04ca52f?page=141"> 894 Ungar et al. a 50 40 30 p</a> <a title="AJG_Vol.113.No6 page 142" href="http://viewer.zmags.com/publication/d04ca52f?page=142"> a 6.0 5.5 g/ml) 5.0 µ 4.5 Ada level ( 4.</a> <a title="AJG_Vol.113.No6 page 143" href="http://viewer.zmags.com/publication/d04ca52f?page=143"> 896 Ungar et al. DISEASE BOWEL INFLAMMATOR</a> <a title="AJG_Vol.113.No6 page 144" href="http://viewer.zmags.com/publication/d04ca52f?page=144"> Our study has several limitations. First, th</a> <a title="AJG_Vol.113.No6 page 145" href="http://viewer.zmags.com/publication/d04ca52f?page=145"> 898 Ungar et al. DISEASE BOWEL INFLAMMATOR</a> <a title="AJG_Vol.113.No6 page 146" href="http://viewer.zmags.com/publication/d04ca52f?page=146"> ARTICLE 899 see related Editorial o</a> <a title="AJG_Vol.113.No6 page 147" href="http://viewer.zmags.com/publication/d04ca52f?page=147"> 900 Jacobs et al. COLON In contrast, amon</a> <a title="AJG_Vol.113.No6 page 148" href="http://viewer.zmags.com/publication/d04ca52f?page=148"> Table 1 Baseline characteristics of participants</a> <a title="AJG_Vol.113.No6 page 149" href="http://viewer.zmags.com/publication/d04ca52f?page=149"> 902 Jacobs et al. COLON Table 2 Adjusted</a> <a title="AJG_Vol.113.No6 page 150" href="http://viewer.zmags.com/publication/d04ca52f?page=150"> our risk estimates are in the same order of magni</a> <a title="AJG_Vol.113.No6 page 151" href="http://viewer.zmags.com/publication/d04ca52f?page=151"> 904 Jacobs et al. Guarantor of the art</a> <a title="AJG_Vol.113.No6 page 152" href="http://viewer.zmags.com/publication/d04ca52f?page=152"> 36. Alberts DS, Martinez ME, Roe DJ, et al. Lac</a> <a title="AJG_Vol.113.No6 page 153" href="http://viewer.zmags.com/publication/d04ca52f?page=153"> 906 ARTICLE </a> <a title="AJG_Vol.113.No6 page 154" href="http://viewer.zmags.com/publication/d04ca52f?page=154"> Many experts believe that “subclinical RAP” is th</a> <a title="AJG_Vol.113.No6 page 155" href="http://viewer.zmags.com/publication/d04ca52f?page=155"> 908 Coté et al. PANCREAS RESULTS Characte</a> <a title="AJG_Vol.113.No6 page 156" href="http://viewer.zmags.com/publication/d04ca52f?page=156"> Table 2 Determinants of lower physical component</a> <a title="AJG_Vol.113.No6 page 157" href="http://viewer.zmags.com/publication/d04ca52f?page=157"> 910 Coté et al. PANCREAS acute pancreatit</a> <a title="AJG_Vol.113.No6 page 158" href="http://viewer.zmags.com/publication/d04ca52f?page=158"> Table 4 Multivariable linear regression model ev</a> <a title="AJG_Vol.113.No6 page 159" href="http://viewer.zmags.com/publication/d04ca52f?page=159"> 912 Coté et al. 15. 16. 17. 18. </a> <a title="AJG_Vol.113.No6 page 160" href="http://viewer.zmags.com/publication/d04ca52f?page=160"> CORRESPONDENCE 913 see related edit</a> <a title="AJG_Vol.113.No6 page 161" href="http://viewer.zmags.com/publication/d04ca52f?page=161"> 914 Correspondence not follow through </a> <a title="AJG_Vol.113.No6 page 162" href="http://viewer.zmags.com/publication/d04ca52f?page=162"> for another reason and I have the patient's prior</a> <a title="AJG_Vol.113.No6 page 163" href="http://viewer.zmags.com/publication/d04ca52f?page=163"> 916 Correspondence Electronic Clinica</a> <a title="AJG_Vol.113.No6 page 164" href="http://viewer.zmags.com/publication/d04ca52f?page=164"> Correspondence 917 To the Editor: Hepa</a> <a title="AJG_Vol.113.No6 page 165" href="http://viewer.zmags.com/publication/d04ca52f?page=165"> 918 Correspondence HCC metastasis to</a> <a title="AJG_Vol.113.No6 page 166" href="http://viewer.zmags.com/publication/d04ca52f?page=166"> Fig. 3 Histological examination showed pseudoacin</a> <a title="AJG_Vol.113.No6 page 167" href="http://viewer.zmags.com/publication/d04ca52f?page=167"> 920 Correspondence </a> <a title="AJG_Vol.113.No6 page 168" href="http://viewer.zmags.com/publication/d04ca52f?page=168"> Financial support: None. </a> <a title="AJG_Vol.113.No6 page 169" href="http://viewer.zmags.com/publication/d04ca52f?page=169"> 922 ANNOUNCEMENT see related editor</a> <a title="AJG_Vol.113.No6 page 170" href="http://viewer.zmags.com/publication/d04ca52f?page=170"> CLASSIFIEDS ADVANCED ENDOSCOPY GASTROENTEROLOGIS</a> <a title="AJG_Vol.113.No6 page 171" href="http://viewer.zmags.com/publication/d04ca52f?page=171"> USA HEALTH The University of South Alabama Healt</a> <a title="AJG_Vol.113.No6 page 172" href="http://viewer.zmags.com/publication/d04ca52f?page=172"> Michael R. Charlton, MD The University of Chicago</a> <a title="AJG_Vol.113.No6 page 173" href="http://viewer.zmags.com/publication/d04ca52f?page=173"> </a>